Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"KindredBio","sponsor":"Elanco","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"$0.5 million","newsHeadline":"Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by KindredBio

    Menu

    KindredBio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              KindredBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody

              Details:

              The collaboration grants Elanco Animal Health an exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. Under the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products.

              Lead Product(s): KIND-030

              Therapeutic Area: Infections and Infectious Diseases Product Name: KIND-030

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Elanco

              Deal Size: $16.5 million Upfront Cash: $0.5 million

              Deal Type: Collaboration December 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY